Conditionally activated, masked biologics platform leveraging tumor-associated proteases to selectively activate biologic therapeutics in the tumor microenvironment; applied across ADCs, T-cell engagers, cytokines, and mRNA modalities for oncology

Discontinued (1)

praluzatamab ravtansine — Breast Cancer · Phase 2 did not show required progression free survival; program deprioritized; CX-2009 License terminated in 2025

Biotech Distilled coverage (3)

2026-04-18 UPDATE: CytomX Therapeutics (CTMX) - Act III of the Institutional Drama 🔒 Paid
2026-03-22 UPDATE: CytomX (CTMX) - Clears the Binary Hurdle and Executes the Classic Biotech Playbook 🔒 Paid
2026-01-28 CytomX Therapeutics (CTMX): Scientific Deep Dive for Varseta-M and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.